Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
- Conditions
- Acute Pathology of the Locomotor System
- Registration Number
- NCT05905146
- Lead Sponsor
- University Hospital, Rouen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria:<br><br> - Patient hospitalized in the rheumatology department<br><br> - Patient with acute pain in the context of a non-cancerous, non-traumatic,<br> high-energy musculoskeletal pathology<br><br> - Patient for whom a prescription of strong opioid derivatives is initiated in<br> rheumatology or patient for whom a prescription of strong opioid derivatives is<br> maintained in rheumatology if the initial prescription has a maximum duration of 30<br> consecutive days prior to inclusion<br><br>Exclusion Criteria:<br><br> - Patient with cancer or fibromyalgia already diagnosed at inclusion<br><br> - Patient with poor French language skills<br><br> - Taking a strong opioid treatment for more than 30 consecutive days prior to<br> inclusion<br><br> - Person judged by the prescriber or pharmacist as not autonomous for the management<br> of strong opioid treatment<br><br> - Patient already included in the study
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method total duration of treatment in days with strong opioids from day of inclusion
- Secondary Outcome Measures
Name Time Method number of patients exceeding the optimal duration of treatment with strong opioids defined by the SFETD learned society (French Society for the Study and Treatment of Pain) (3 months);pain assessment (numerical scale) at first patient call after stopping strong opioids;number of patients exceeding the optimal duration of treatment with strong opioids defined by the CLUD (Pain Control Committee) of Rouen University Hospital (28 days)